John Kilroy
Analyst · Citi. Please go ahead
Thank you, Tyler. Hello, everyone and thank you for joining us today. We continue to see healthy fundamentals across all of our West Coast markets. During the first six months of 2017, we executed leases on more than 1.1 million square feet in our stabilized portfolio. Rents on these leases were up 14% on a cash basis and 30% on a GAAP basis and the level of leasing was more than double the amount we leased in the first half of 2016. Looking back in time a bit, over the last 15 quarters our stabilized portfolio has never been less than 95% leased and our consistent leasing success has generated an average cash, same store growth in excess of 7%. In the second quarter, we signed new or renewing leases in our stabilized portfolio on just under 490,000 square feet of space that have rents that were 13% higher on a cash basis and 32% higher on a GAAP basis. This included a 141,000 square foot lease extension with Neurocrine, one of our San Diego based life science tenants. Neurocrine's lease was expiring in 2019 and our team did a terrific job working with the tenant to extend the lease for an additional ten years. At quarter end, the stabilized portfolio was 93.9% occupied and 96% leased. In following quarter end, we signed leases at Colombia Square that takes the office component of that project to 100% leased. We also made progress on our $1.4 billion in process development program. In June, we initiated construction at 333 Dexter, our first ground-up development project in Seattle. Market conditions in Seattle are among the strongest in the nation and the South Lake Union submarket where 333 Dexter is located, has strong demand, minimal vacancy and little new supply. Construction continues on time and on budget at 100 Hooper in San Francisco. The office portion is 100% leased to Adobe and we are beginning to see real interest in the 86,000 square feet of PDR space. Two are activity and request for proposals at the exchange, our state of the art office and life science facility in Mission Bay has accelerated as the buildings are now fully visible along the freeway. We continue to see strong interest and remain confident that it will be largely leased by completion next year. At One Paseo, our mixed use project in Del Mar, construction continues on overall site infrastructure, 237 residential units and 96,000 square feet of retail space. This work will be completed in phases beginning in the third quarter of 2018. We are making substantial leasing progress on the retail space where several key destination tenants, primarily food and beverage, have committed to the project and are driving increased demand from a variety of other experiential oriented retailers. In summary, over the next two years, we will deliver approximately $1.4 billion of new state-of-the-art projects that are diversified in terms of product type and market. Projected cash returns averaged 7% to 8% and given current market pricing for similar product, the value could be double our investment. On the financial front, we increased our quarterly dividend 13% to an annualized rate of $1.70 per share. And in July, we strengthened our overall access to capital by amending our credit facility to increase the size by 25% to $750 million, to extend term until 2022 and to lower pricing. Combined with our bank loan facility, our bank term loan facility rather, we now have a total borrowing capacity of up to $1.5 billion including the accordion feature. With regard to capital recycling, we are making progress on the sale of non-strategic assets that would put us in line with the midpoint of our disposition guidance range we provided for the year. Finally, I would like to introduce two very talented and experienced real estate professionals who have joined our management team. Steve Rosetta came aboard in June as our Chief Financial - or rather our Chief Investment Officer. He has been working with our team on several Bay area and San Diego transactions over the past year. Steve has extensive experience in both strategic and transactional aspects of office and life science real estate; most recently as Vice Chairman of Cushman & Wakefield. He will now be working with me to guide our strategic growth, uncover new opportunities and assist in large office and life science leases. Steve is a proven deal maker with a strong track record for executing complex transactions and we're delighted to welcome him to our team. Also joining our team in August is Eliott Trencher who many of you on this call know well. Eliott has extensive experience in the evaluation of both office and life science real estate at the project portfolio and enterprise level. He has spent the last nine years as an analyst, portfolio manager and member of the investment committee for Cohen & Steers. He will work closely with Steve to help us evaluate new opportunities, capital recycling projects and other strategic initiatives. As I've said on prior calls, I believe KRC has one of the deepest benches in our industry and the strongest platform on the West Coast. With Steve and Eliott joining us, our capabilities grow even stronger. Through the first half of 2017, our West Coast markets continue to exhibit healthy fundamentals with strong leasing and rising rental rates for top quality well-located properties. We are capitalizing on these conditions with highly efficient and sustainable work environments that appeal to the broad range of technology in the innovative driven industries and we are willing to make well considered prudent investments in emerging opportunities that we believe in. Our early cycle moves in both San Francisco and Seattle and our more recent focus on strengthening our life science capabilities are both examples of this. That completes my remarks, now I'll turn the call over to Jeff for a closer look at our markets. Jeff?